Aigen Investment Management’s Myriad Genetics MYGN Stock Holding History

Aigen Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,008	Closed	-$376K	–	798
2020 Q4	$376K	Sell	19,008 -50,514	-73%	-$816K	0.05%	485
2020 Q3	$907K	Buy	+69,522	New	+$880K	0.12%	272
2020 Q2	–	Sell	-15,728	Closed	-$225K	–	1131
2020 Q1	$225K	Buy	15,728 +15,513	+7,215%	+$328K	0.03%	673
2019 Q4	$6K	Buy	+215	New	+$5.92K	﹤0.01%	994

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Aigen Investment Management's MYGN Position: Q1 2021 in Review

Aigen Investment Management sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 19,008 shares — an estimated $376K sold.

Aigen Investment Management first reported a position in MYGN in Q4 2019 and held it in 4 quarters. The position peaked at $907K in Q3 2020. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Aigen Investment Management reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Aigen Investment Management sold 19,008 Myriad Genetics shares in Q1 2021, an estimated $376K.
Aigen Investment Management first reported a position in Myriad Genetics in Q4 2019 and held it in 4 quarters.
Aigen Investment Management's Myriad Genetics position peaked at $907K in Q3 2020.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Aigen Investment Management's 13F filing for Q1 2021, filed 11 May 2021.